Brokerages forecast that ANCHIANO THERAP/S (NASDAQ:ANCN) will post earnings per share of ($0.16) for the current quarter, according to Zacks. Zero analysts have issued estimates for ANCHIANO THERAP/S’s earnings. The company is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that ANCHIANO THERAP/S will report full-year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.57) to ($0.80). For the next year, analysts expect that the business will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.97) to ($0.64). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow ANCHIANO THERAP/S.
ANCHIANO THERAP/S (NASDAQ:ANCN) last issued its earnings results on Monday, August 5th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.11.
Several large investors have recently modified their holdings of the company. FMR LLC bought a new stake in shares of ANCHIANO THERAP/S during the first quarter valued at approximately $288,000. Kennedy Capital Management Inc. acquired a new stake in shares of ANCHIANO THERAP/S in the first quarter valued at approximately $1,359,000. Delek Group Ltd. acquired a new stake in shares of ANCHIANO THERAP/S in the first quarter valued at approximately $176,000. Finally, Meitav Dash Investments Ltd. acquired a new stake in shares of ANCHIANO THERAP/S in the first quarter valued at approximately $177,000. 11.17% of the stock is currently owned by institutional investors.
Shares of NASDAQ:ANCN traded up $0.22 during mid-day trading on Thursday, reaching $2.79. The stock had a trading volume of 27,261 shares, compared to its average volume of 13,544. The firm has a market cap of $20.18 million and a P/E ratio of -0.53. ANCHIANO THERAP/S has a 1 year low of $2.49 and a 1 year high of $11.50. The business has a 50 day moving average of $3.89.
ANCHIANO THERAP/S Company Profile
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.
Further Reading: What is an investor looking for in an SEC filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.